Guardant Health
Guardant Health Inc is a precision oncology company headquartered in Palo Alto, California. The company develops non-invasive liquid biopsy tests, proprietary bioinformatic platforms, and diagnostic assays for cancer detection. Its primary commercial products include blood tests used for advanced cancer profiling, therapy selection, and recurrence monitoring. Revenue is derived from clinical test volume fees billed to insurance providers alongside biopharmaceutical research collaboration agreements. The company serves oncologists, research institutions, and pharmaceutical enterprises across global oncology markets. Guardant Health Inc is publicly traded on the Nasdaq Global Select Market.
20 of the funds FundTelligence covers report a position in Guardant Health.
- Legal name
- GUARDANT HEALTH INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 20
- Exposure themes
- Liquid Biopsy, Molecular Diagnostics, Precision Medicine & Genomics
Funds holding Guardant Health
- Norse Trend Global — Norse · 4.4 % (largest positions only, October 2026)
- GS Global Future Health Care Equity Portfolio — Goldman Sachs · 4.03 % (largest positions only, September 2026)
- UBS Biotech Equity Fund — UBS · 4.0 % (largest positions only, September 2026)
- Polar Capital Healthcare Discovery Fund — Polar Capital · 3.8 % (largest positions only, October 2026)
- SEB US Focus Core — SEB · 3.5 % (largest positions only, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 3.02 % (full portfolio disclosed, September 2026)
- BGF Next Generation Health Care Fund — BlackRock · 2.79 % (largest positions only, January 2026)
- Handelsbanken Helse Tema — Handelsbanken · 1.96 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 20 funds holding it.